Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes
FOX, ET AL. 2019. SCI IMMUNOL, 4(32): EAAV5062
Where research scientists come to find up to date resources on antibody discovery against challenging membrane protein targets.
FOX, ET AL. 2019. SCI IMMUNOL, 4(32): EAAV5062
LONG, ET AL. 2019. PNAS DOI: 10.1073/PNAS.1815432116.
SAPHIRE, ET AL. 2018. CELL 174(4):938-952
FLYAK. 2018. NATURE MICROBIOLOGY 3, 670-677.
SULLIVAN, ET AL. 2017. J VIROL 91(22), E00862-17.
GOPAL, ET AL. 2017. PLOS PATHOGENS 13(12), E1006735.
ZHAO ET AL. 2017. CELL 169, 891-904.
HOWELL ET AL. 2017. CELL REP 19(2), 413-424.
NIVARTHI ET AL. 2017. J VIROL 91(5), E02041-02056.